Actinium Pharmaceuticals (ATNM) investor relations material

Investment thesis and strategic positioning

• Differentiated radiotherapy pipeline shaped by deep disease biology understanding, with key data readouts expected in 2026 and a cash runway into 2028.

• Two solid tumor assets (ATNM-400 and Actimab-A MDSC) target pan-cancer opportunities, including prostate, lung, and breast cancer.

• Hematology and conditioning franchise is late-stage and partner-ready, addressing the full AML treatment journey and cell/gene therapy conditioning.

• Robust R&D, expanding in-house manufacturing, and strong IP portfolio (~250 patents) support near-term catalysts.

• Clean capital structure with $36.5M cash, no debt, and 31.4M shares outstanding as of June 2026.

Radiopharma landscape and market opportunity

• Industry dominated by a few targets (PSMA, SSTR2, FAP) and large pharma with underutilized infrastructure.

• Over $17B in M&A and $10B+ in investments highlight demand for differentiated radiotherapy assets.

• Current landscape features undifferentiated programs from 50+ smaller companies and 6 big pharma players.

• Urgent need for novel assets due to sparse pipelines post-M&A wave.

Pipeline overview and innovation

• Three high-value pillars: solid tumors (ATNM-400, Actimab-A MDSC), hematology (Actimab-A, lomab-B), and conditioning (lomab-ACT).

• ATNM-400 is a first-in-class Ac-225 program for mCRPC, NSCLC, and breast cancer; Actimab-A MDSC targets resistance in solid tumors.

• Late-stage hematology assets address AML and MDS, with universal conditioning for cell/gene therapies.